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Abstract
Background: Alpha-1 antitrypsin (A1AT) deficiency, caused by the Z allele (p.E342K) and S allele (p.E264V) in the
SERPINA1 gene, can induce liver and pulmonary disease. Different mechanisms appear to be responsible for the
pathogenesis of these divergent disease expressions. The c.-1973T >C polymorphism located in the SERPINA1
promoter region is found more frequent in A1AT deficiency patients with liver disease compared to patients with
pulmonary disease, but data are lacking regarding contribution to the development of liver diseases caused by
other aetiologies.
Aim: To study the prevalence of c.-1973T >C, Z allele and S allele in a cohort of patients with liver disease of
various aetiologies compared with healthy controls and to evaluate its effect on disease progression.
Methods: A total of 297 patients with liver disease from various aetiologies and 297 age and gender matched
healthy controls were included. The c.-1973T >C polymorphism and Z and S alleles of the SERPINA1 gene were
analyzed by real-time PCR.
Results: c.-1973T >C was similarly distributed between patients with liver disease of various origins and healthy
controls. Furthermore, the distribution of c.-1973T >C was independent from aetiology subgroup. In patients with
liver disease mean ages at of onset of liver disease were 44.4, 42.3 and 40.7 years for the c.-1973 T/T, T/C and C/C
genotype respectively (NS). S allele heterozygosity was increased in patients with drug induced liver injury (DILI),
(OR 4.3; 95%CI 1.1-17.2).
Conclusion: In our study, c.-1973T >C polymorphism was not a risk factor for liver disease of various aetiologies. In
addition, S allele heterozygosity might contribute to the development of DILI.
Background
Alpha-1 antitrypsin (A1AT) deficiency is a hereditary
disease and can induce end-organ damage caused by
defective A1AT protein processing. Liver disease in
A1AT deficiency is caused by hepatic accumulation of
the A1AT protein and pulmonary disease is induced by
an impaired protection against neutrophil elastase due
to decreased serum A1AT[1,2]. The A1AT protein is
encoded by the protease inhibitor (Pi) locus located on
chromosome 14q32.1 (SERPINA1 gene). In Western
Europe, A1AT deficiency most commonly results from
presence of 2 genetic variants p.E342K (denoted as
Z allele) and p.E264V (commonly referred to as the
S allele)[3]. Liver disease in A1AT deficiency has a
bimodal presentation affecting children in neonatal life
[4] and, less commonly, adults in late middle life[5].
It is unclear why A1AT deficiency leads to liver dis-
ease in some patients and lung disease in others. It
appears that environmental factors are in part responsi-
ble for this difference. Pulmonary disease develops pre-
ferably in homozygous Pi ZZ persons who are tobacco
smokers or are exposed to airway irritants[6]. Indeed,
smoking is an established risk factor for lung disease as
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considerable younger age, while non-smokers are at risk
for liver disease developing later in life[7]. Some 32-37%
of A1AT deficient non-smoking patients will die as a
result of A1AT deficiency induced liver disease[8].
Apart from environmental factors there is some evi-
dence that genetic factors modify the risk for A1AT
deficiency related end-organ damage. For example, 72%
of siblings of probands with A1AT deficiency related
liver disease suffered from liver disease, which was con-
cordant for severity in 29%, while 28% had no liver
involvement[9]. This suggests presence of genetic modi-
fiers. Indeed a recent study identified a novel single
nucleotide polymorphism (SNP) g.126076T >C (c.-1973T
>C; rs8004738) in the promoter region of SERPINA1.I t
appeared that the SNP was enriched (15.5%) in a cohort
of A1AT Pi ZZ homozygotes with liver disease relative
to those with pulmonary disease (6.5%)[10].
As a result of the above-mentioned observations we
hypothesized that c.-1973T >C polymorphism affects
susceptibility for the progression of liver disease in
patients with liver disease of various aetiologies. There-
fore we investigated the association of c.-1973T >C,
p.E342K (Z allele) and p.E264V (S allele) polymorphisms
in a cohort of patients with liver disease of various
aetiologies compared with healthy controls and evalu-
ated its consequence on course of disease.
Methods
Patients
We recruited patients with various liver disorders, visit-
ing the outpatient clinic of the Department of Gastroen-
terology and Hepatology oft h eR a d b o u dU n i v e r s i t y
Nijmegen Medical Center. In addition, age and gender
matched persons who were unrelated to our patients
served as healthy controls. In the patient population,
clinical and demographic data including age, sex, age at
first presentation of liver disease, aetiology of liver dis-
ease and presence or absence of cirrhosis were obtained.
The absence of liver disease in our control population
was established on the basis of self-reporting and none
of the patients used any medication. Whole blood sam-
ples were stored at -20°C. Altogether the study popula-
tion comprised 297 patients with various aetiologies of
liver disease and 297 controls. Clinical and demographic
data are given in Table 1. The study was approved by
the local ethical committee (Medical Ethical Committee
of the Radboud University Nijmegen Medical Center)
and all subjects gave their informed consent.
Laboratory
DNA was isolated from peripheral blood using the High
Pure PCR Template preparation kit (Roche, Mannheim,
Germany). The c.-1973T >C (rs8004738), p.E342K
(Z allele; c.1024G > A; rs28929474) and p.E264V
(S allele; c.791A > T; rs17580) polymorphisms of the
SERPINA1 gene were analyzed by real-time polymerase
chain reaction (PCR) using a dual-color, allele-specific
discrimination assay with fluorescent labelled probes on
the iCycler iQ Multicolour real-time detection system
(Bio-Rad Laboratories Inc, Hercules, CA, USA). Primer
and probe sequences (Sigma, St Louis, MO, USA) used
for PCR and real time detection are listed in additional
file 1. All of the genotyping results in the control popu-
lation were in the Hardy-Weinberg equilibrium. Haplo-
types and diplotypes were determined using the
Partition-Ligation-Expectation-Maximization (PLEM) 1.0
software [11].
Statistical analysis
Baseline characteristics, differences in allele frequency,
diplotypes and haplotypes were analyzed using student
t-tests, Pearson chi-squared test and Fisher’s exact test
when appropriate. Odds Ratio’s (OR) were calculated for
the association between the studied polymorphisms and
the presence of liver disease. In addition we calculated
OR’s for the association between the 3 polymorphisms
and all different subgroup aetiologies. We analyzed dif-
ferences in age at onset of liver disease between the 3
different c.-1973 genotypes using ANOVA. All statistical
analyses were performed using GraphPad Prism Version
4.02 (GraphPad Software Inc., San Diego, CA, USA).
A two-sided p-value of < 0.05 was considered statisti-
cally significant. Post-hoc power calculation showed the
study being adequate powered (88%) to negate our
Table 1 Baseline characteristics of patients and controls.
Patients Controls p-
value
(n = 297) (n = 297)
Male (%) 168 (57) 163 (55) 0.74
Mean age (range) 51.4 yrs (19-
85)
51.5 yrs (20-
85)
0.94
Mean age at onset liver disease
(range)
43 yrs (7-82)
Cirrhosis (%) 69 (23)
Cause of liver disease (%)
-HCV 129 (43)
-AIH/PBC/PCS 53 (18)
-HBV 50 (17)
-Alcoholic liver disease 21 (7)
-NASH/metabolic 16 (5)
-Cryptogenic 13 (4)
-Drug induced liver injury 11 (4)
-Vascular 4 (1)
HCV = hepatitis C virus, AIH/PSC/PBC = autoimmune hepatitis/primary biliary
cirrhosis/primary sclerosing cirrhosis, HBV = hepatitis B virus, NASH = non-
alcoholic steato hepatitis
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ease of various aetiologies (a = 0.05, difference in group
proportions 10% (20% and 30%)). Power calculations
were performed using nQuery Advisor 4.0 software
(Statistical Solutions Ltd, Cork, Ireland). Linkage dise-
quilibrium (LD) values were performed with Haploview
4.0 software.
Results
C polymorphism",1,0,1,0,0pc,0pc,0pc,0pc>c.-1973T > C
polymorphism
The c.-1973T >C polymorphism distribution in 297
patients with liver disease due to various aetiologies was
in line with 297 healthy controls. (c.-1973:T / T3 2 % ,
T/C 44% and C/C 24% in patients and T/T 30%, T/C
50% and C/C 20% in controls). (Figure 1) We found no
association of the c.-1973T >C polymorphism with any
of the distinct liver diseases investigated. Next, we
observed that mean age at onset of liver disease was
non-significantly lower in patients with the c.-1973 C/C
allele, as mean ages of onset of liver disease were 44.4
(T/T), 42.3 (T/C) and 40.7 (C/C) years. (Figure 2)
Further, possession of c.-1973T >C polymorphism had
no influence on the presence of cirrhosis.
Z (p.E342K) allele and S (p.E264V) allele heterozygosity
We observed a similar Z allele and S allele heterozygos-
ity rate in patients and controls (Z allele: 3.0% and 4.7%;
S allele: 6.7% and 8.0%). The distribution of Z allele het-
erozygosity was similar among all liver diseases of var-
ious aetiologies. In contrast, S allele heterozygosity was
more frequently present in drug induced liver injury
(DILI) compared with healthy controls (11 patients, 27%
vs 8%; OR 4.27; 95%CI 1.06-17.15). A total of 8 wildtype
patients developed DILI likely due to clavulanic acid
(n = 3), azatioprine, sulfasalazine, pantoprazole, metho-
trexate and quetiapine; addionally, the S allele heterozy-
gotes had DILI caused by anaesthetic compounds
(isoflurane/nestonal), clavulanic acid and celecoxib.
Lastly, age at onset of liver disease was independent of
Z or S allele heterozygosity as mean ages were 48.3
(Z allele), 43.2 (S allele) and 42.4 (wildtypes) years.
Haplotyping/diplotyping
Based on the 3 polymorphisms tested, haplotype and
diplotype analysis were performed. A total of 11 diplo-
types could be distinguished. We could not detect differ-
ences in diplotypes between patients with liver disease
of various etiologies and controls. Only the CTG haplo-
type was more frequent found in patients with DILI,
according to the above-described association between
S allele heterozygosity and DILI. (Table 2) Finally, link-
age disequilibrium (LD) between the 3 SERPINA1 alleles
was absent. This was true for patients as well as con-
trols. (Figure 3)
Figure 1 Distribution of the c.-1973T >C genotypes in 297
patients with liver disease of various aetiologies and 297
controls.
Figure 2 Age at onset of liver disease in 297 patients arranged
to the different c.-1973T >C genotypes.
Table 2 Diplotypes in patients with liver disease of
various aetiology and healthy controls
Diplotype Controls (%) Patients (%)
n = 297 n = 297
CAG/TAG 130 (43.8) 112 (37.7)
TAG/TAG 78 (26.3) 93 (31.3)
CAG/CAG 51 (17.2) 63 (21.2)
CTG/TAG 11 (3.7) 12 (4.0)
CAG/CTG 8 (2.7) 7 (2.4)
TAG/TAA 8 (2.7) 2 (0.7)
CAG/TAA 5 (1.7) 6 (2.0)
TAG/TTG 4 (1.3) 1 (0.3)
CTG/TAA 1 (0.3)
CTG/CTG 1 (0.3)
CAG/CAA 1 (0.3)
Order of alleles: c.-1973T >C- c.791A > T - c.1024G > A/c.-1973T >C- c.791A > T
- c.1024G > A (mutations in bold)
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We show that the distribution of SERPINA1 c.-1973T
>C in patients with liver disease from various aetiologies
is similar compared to healthy controls. The genotype
frequencies in the patient and control groups were in
line with those from the HapMap database (TT 30%,
T/C 45% and C/C 25%) [12]. Moreover, we found that
the distribution of c.-1973T >C is independent from
aetiology of the liver disease. We also examined whether
the c.-1973T >C polymorphism affected age at onset
of liver disease. We found a non-significant lower
age at onset in patients with the c.-1973 C/C genotype
compared to other c.-1973 genotypes. In addition, we
could not demonstrate an association of c.-1973T >C on
severity of liver disease e.g. cirrhosis. We also investi-
gated other SERPINA1 variants and found that there
was no increased prevalence of Z and S alleles in
patients with liver disease of various aetiologies com-
pared with healthy controls, even though we observed
an enrichment of S allele heterozygosity in patients with
DILI.
Other investigators have studied the presence of
c.-1973T >C and A1AT deficiency and chronic obstruc-
tive pulmonary disease (COPD). Chappell et al. reported
an enrichment of c.-1973T >C in homozygous Pi ZZ
neonates with hepatitis (15.5%) compared to homozy-
gous Pi ZZ controls (adults with COPD and unaffected
subjects) (6.5%)[10]. Since our study population con-
sisted for a large extent of patients and controls with
the Pi MM genotype (wildtypes) and hardly any subjects
with Z and S allele heterozygosity, we cannot compare
our data with the results of the above mentioned study.
Another study showed a decreased prevalence of
c.-1973T >C in patients with COPD (48.7%) compared
to controls (52.2%), suggesting a protective effect against
COPD[13]. It might be possible that c.-1973T >C influ-
ences the genesis of liver disease in childhood, in line
w i t har e c e n t l yp u b l i s h e dr e p ort implicating that a var-
iant of the endoplasmic reticulum mannosidase
I (ERManI) gene is associated with an early onset of
end-stage liver disease in patients with homozygous
(Pi ZZ) A1AT deficiency[14].
Figure 3 Linkage disequilibrium (LD) plot across the SERPINA1 gene. Patients. Controls. The box at the top indicates the SERPINA1 gene
with the 3 investigated SNP’s( 1=p.E342K,2=p.E264V and 3 = c.-1973T >C). The LD plot is based on the measurement of R
2 (values × 0.01).
Each diamond indicates the pair wise magnitude of LD. (LD: linkage disequilibrium is the non-random association of alleles at two or more loci.
LD describes a situation in which some combinations of alleles or genetic markers occur more or less frequently in a population than would be
expected from a random formation of haplotypes from alleles based on their frequencies.)
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S allele heterozygosity were previously associated with
(end-stage) liver disease due to HCV, alcoholic liver dis-
ease and cryptogenic cirrhosis [15-19] and not with
DILI. We found a higher frequency of S allele hetero-
zygosity in DILI patients. Indeed, experimental evidence
supports a relation between A1AT deficiency and DILI
as administration of indom e t h a c i ni nah o m o z y g o u sP i
ZZ mouse model leads to increased hepatic injury [20]
and a case report described prochlorperazine induced
liver injury in a homozygous (Pi ZZ) A1AT deficient
patient [21].
We could not demonstrate an association between
c.-1973T >C and the presence of cirrhosis. There have
been several genetic case control studies that have
attempted to detect associations between genetic varia-
tions and liver fibrosis. For example, the combination of
angiotensinogen (ATG) gene variant c.1-44 and trans-
forming growth factor beta (TGFb1) p.R25P is asso-
ciated with advanced hepatic fibrosis in obese patients
with non alcoholic fatty liver disease [22] but not in
patients with other chronic liver diseases[23]. Lastly,
matrix metalloproteinase (MMP)-7(Asp-137) confers
risk of liver cirrhosis[24].
Our study comes with limitations. Our cohort could
have suffered from selection bias due to patient recruit-
ment in a tertiary referral centre. The strength of our
study is the sufficiently power to negate a 10% differ-
ence in prevalence of the c.-1973T >C polymorphism
between groups. However, the study lacks power to
demonstrate smaller differences and to perform a thor-
ough subgroup analysis. Further research regarding
c.-1973T >C should include homozygous Pi ZZ adults
with liver disease to evaluate whether c.-1973T >C is a
risk factor for a hepatic expression of A1AT deficiency.
Conclusion
We demonstrated that, in our study, c.-1973T >C poly-
morphism was not associated with liver disease of var-
ious aetiologies. In addition, S allele heterozygosity
might be a risk factor for the genesis of DILI.
Additional file 1: Overview of primers and probes used for real
time PCR reactions.
Click here for file
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